Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library

Gene Therapy

Volumn 17, Issue 8, 2010, Pages 980-990

  Ying, Y ^a,d   Muller O J ^b   Goehringer, C ^b   Leuchs, B ^a   Trepel, M ^c   Katus, H A ^b   Kleinschmidt, J A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AAV; heart; vector targeting

Indexed keywords

ADENOVIRUS VECTOR; DELTA SARCOGLYCAN; PEPTIDE LIBRARY;

ADENOVIRUS 2; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOPANNING; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HEART; HEART MUSCLE CELL; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VIRUS CAPSID;

ANIMALS; CELL LINE; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; PEPTIDE LIBRARY; RATS; SARCOGLYCANS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS - 2; MUS;

EID: 77955654722     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.44     Document Type: Article

References (57)

1. Muzyczka N, Warrington Jr KH. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005; 16: 408-416.
2. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830-844.
3. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
4. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-427.
5. Le Bec C, Douar AM. Gene therapy progress and prospects\vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006; 13: 805-813.
6. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-591.
7. Buning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J et al. Receptor targeting of adeno-associated virus vectors. Gene Ther 2003; 10: 1142-1151.
8. Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008; 16: 1703-1709.
9. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82: 5887-5911.
10. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008; 16: 1252-1260.
11. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297.
12. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17: 181-186.
13. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas Jr M. Conjugate-based targeting of recombinant adeno-asso-ciated virus type 2 vectors by using avidin-linked ligands. J Virol 2002; 76: 12900-12907.
14. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther 2006; 14: 97-106.
15. Ried MU, Girod A, Leike K, Buning H, Hallek M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol 2002; 76: 4559-4566.
16. Gigout L, Rebollo P, Clement N, Warrington Jr KH, Muzyczka N, Linden RM et al. Altering AAV tropism with mosaic viral capsids. Mol Ther 2005; 11: 856-865.
17. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
18. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med 2006; 8: 155-162.
19. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24: 198-204.
20. Warrington Jr KH, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004; 78: 6595-6609.
21. Lux K, Goerlitz N, Schlemminger S, Perabo L, Goldnau D, Endell J et al. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J Virol 2005; 79: 11776-11787.
22. Loiler SA, Conlon TJ, Song S, Tang Q, Warrington KH, Agarwal A et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 2003; 10: 1551-1558.
23. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12: 1697-1711.
24. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74: 8635-8647.
25. Yang Q, Mamounas M, Yu G, Kennedy S, Leaker B, Merson J et al. Development of novel cell surface CD34-targeted recombi-nant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998; 9: 1929-1937.
26. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, Bettinger K et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 2003; 77: 11072-11081.
27. Opie SR, Warrington Jr KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003; 77: 6995-7006.
28. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-975.
29. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003; 7: 515-525.
30. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004; 109: 513-519.
31. Work LM, Nicklin SA, Brain NJ, Dishart KL, Von Seggern DJ, Hallek M et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198-208.
32. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U et al. Efficient and selective aav2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
33. Perabo L, Buning H, Kofler DM, Ried MU, Girod A, Wendtner CM et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157.
34. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21: 1040-1046.
35. Waterkamp DA, Muller OJ, Ying Y, Trepel M, Kleinschmidt JA. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 2006; 8: 1307-1319.
36. Bupp K, Roth MJ. Altering retroviral tropism using a random-display envelope library. Mol Ther 2002; 5: 329-335.
37. Bupp K, Sarangi A, Roth MJ. Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries. J Virol 2005; 79: 1463-1469.
38. Muller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006; 70: 70-78.
39. Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
40. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, Kleinschmidt JA et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS ONE 2009; 4: e5122.
41. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, Hadhazy MA et al. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 2000; 113 (Part 14): 2535-2544.
42. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834.
43. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
44. Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005; 11: 57-65.
45. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99: e3-e9.
46. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini 3rd FC et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125: 385-398.
47. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073-1080.
48. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009; 106: 3946-3951.
49. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003; 10: 2139-2147.
50. Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005; 112: 2650-2659.
51. Dubielzig R, King JA, Weger S, Kern A, Kleinschmidt JA. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol 1999; 73: 8989-8998.
52. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
53. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7: 839-850.
54. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111.
55. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381-6388.
56. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000; 316: 743-761.
57. Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, Zeller WJ et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002; 6: 272-278.